Oncolytics Biotech, a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, announced today that it has reached an agreement with the NCIC Clinical Trials Group (NASDAQ:CTG) at Queen's University in Kingston, Ontario, under which the NCIC CTG will fund and perform a Phase II study of the effectiveness of REOLYSIN® in patients with advanced or metastatic colorectal cancer.
"We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics. "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining REOLYSIN with Avastin®. As a Company, we intend to continue expanding our clinical program to include randomized studies of frequently diagnosed cancers."
The Phase II open-label, randomized, non-blinded, clinical study will be examining the difference in effectiveness between REOLYSIN when given in combination with FOLFOX-6 plus bevacizumab (Avastin) and the effectiveness of FOLFOX-6 plus bevacizumab alone. Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.
For further information about Oncolytics, please visit: www.oncolyticsbiotech.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html